Patent application number | Description | Published |
20080234657 | METHODS FOR CONTRIBUTING TO CARDIOVASCULAR TREATMENTS - Disclosed herein are methods that can contribute to cardiovascular treatments. The methods are designed to provide bioactive materials to the first proximal third of coronary arteries, the portion of these arteries most likely requiring treatment. | 09-25-2008 |
20080245375 | Benign Prostatic Hyperplasia Treatments - Disclosed herein are methods to treat benign prostatic hyperplasia (BPH) using bioactive-material eluting medical devices. | 10-09-2008 |
20090238815 | Nondegradable Hydrogels For Medical Device Application - Disclosed are nondegradable hydrogels used to coat or form at least a portion of a medical device. The hydrogels may be formed from functionalized PEG based macromers. These hydrogels are easy to sterilize, transport and store. Methods of forming these hydrogels as described herein are included. | 09-24-2009 |
20100124533 | Large Animal Model for Human-Like Advanced Atherosclerotic Plaque - An animal model for cardiovascular disease comprising one or more vascular plaque lesions formed at selected sites within a vascular segment of a nonhuman mammal. The vascular plaque lesion is formed by administering a hypercholesterolemic diet to the nonhuman mammal, inflicting an injury to the vascular wall at the selected site after a predetermined exposure to the hypercholesterolemic diet, and applying a hydrogel to the injured vascular wall. Another aspect of the invention provides a method for evaluating a test compound for an effect on atherosclerotic lesion formation comprising administering to a nonhuman mammal a hypercholesterolemic diet, and, after a defined period of time, isolating a segment of a blood vessel using a balloon catheter, inflicting an injury to the vascular wall within the isolated segment, and applying a hydrogel within the vascular segment. The method further comprises forming a vascular plaque lesion on the vascular wall at the site of the injury, delivering the test compound to the nonhuman mammal, and monitoring atherosclerotic lesion size and composition at the injured site after a defined period of exposure to the test compound. | 05-20-2010 |
20100226893 | High Retention Cell Injectate - The present disclosure generally relates to high retention cell injectates, methods of producing the high retention cell injectates and further to methods of treating diseases or conditions by administering the cell injectates to patients in need thereof. To allow for cell rentention into a provided hyaluronic acid solution, the present disclosure provides pretreatment of cells with one or more substances that increases the number of CD44 receptors on their surfaces. Cells expressing CD44 ligands show increase in binding to hyaluronic acid. The pretreated cells are thus incorporated into hyaluronic acid. | 09-09-2010 |
20100227799 | SIMULTANEOUS PHOTODYNAMIC THERAPY AND PHOTO INDUCED POLYMERIZATION - Described herein are methods and compositions for the combined treatments of photodynamic therapy and photo-induced polymerization. The wavelength of light needed to accomplish both therapies can be different or can be the same. In one embodiment, the photodynamic therapy is performed first and the photo-induced polymerization is performed thereafter. In other embodiments, both treatments are performed simultaneously. | 09-09-2010 |
20100241163 | Aortic Dissection Treatment System and Method of Use - An aortic dissection treatment system and method of use including a treatment system for an aortic dissection having a catheter defining a suction lumen and a sealant lumen; a flexible cup defining an isolation region within the flexible cup, the isolation region being in communication with the suction lumen and the sealant lumen; and a sealant fluid deliverable to the aortic dissection through the sealant lumen and the isolation region. The flexible cup is sized to fit over at least one end of the aortic dissection and the suction lumen applies suction to maintain the flexible cup over the at least one end of the aortic dissection. | 09-23-2010 |
20100268191 | Drug Delivery Catheter using Frangible Microcapsules and Delivery Method - A drug delivery catheter and method are provided for delivering drugs to a targeted region of a lumen include drug-laden microcapsules provided within a porous catheter balloon with an effective pore size that prevents free-flow of the microcapsules through the porous wall of the balloon. The microcapsules are frangible under the influence of increased pressure within the balloon. In an alternative embodiment, the microcapsules may be mechanically ruptured by compression between the outer porous balloon and optional, inner, non-porous balloon. The drug is emitted from the microcapsules through the balloon pores and against the targeted luminal surface. | 10-21-2010 |
20110218606 | Methods for Stabilizing Femoral Vessels - The invention provides methods for stabilizing the femoral artery. | 09-08-2011 |
20110266720 | System and Method for Stent Manufacture - The system and method for stent manufacture includes a method of supercritical stent manufacture including mixing a polymer and a supercritical fluid to form a supercritical mixture; electrically charging a mold to a first polarity, the mold having a mold wall defining a mold plenum; discharging the supercritical mixture through a nozzle; electrically charging the supercritical mixture to a second polarity opposite the first polarity; repeatedly directing the charged supercritical mixture into the mold plenum to form a plurality of polymer layers on the mold wall, the plurality of polymer layers having a predetermined thickness; and separating the plurality of polymer layers from the mold wall. | 11-03-2011 |
20130116737 | Methods for Assessing Renal Neuromodulation Treatment and Associated Systems and Methods - The present technology relates to methods for assessing renal neuromodulation treatment and associated systems and methods. In particular, various embodiments of the present technology relate to assessing the efficacy of an ongoing or completed renal neuromodulation procedure and providing feedback (e.g., visual and/or audible indications) to a clinician with the results of all or part of such procedures. | 05-09-2013 |